Davidson C J, Hlatky M, Morris K G, Pieper K, Skelton T N, Schwab S J, Bashore T M
Duke University Medical Center, Durham, North Carolina.
Ann Intern Med. 1989 Jan 15;110(2):119-24. doi: 10.7326/0003-4819-110-2-119.
To determine the incidence of cardiovascular and renal toxicity of a nonionic contrast agent when used for cardiac catheterization, and to assess the value of electrolytes and urinalysis results as predictors of nephropathy induced by a contrast agent.
Nonrandomized trial using a criterion standard and a cohort analytic study with a 48-hour follow-up.
Referral-based university hospital.
Convenience sample of patients having diagnostic cardiac catheterization. Renal function and clinical status were evaluated at baseline in 1,144 patients; at 24 hours in 1,077 (94%); and at 48 hours in 663 (57%).
After patients received saline for hydration, coronary angiography and left ventriculography were done with iopamidol (average dose, 203 +/- 56 cc).
The definite and possible incidence of major acute cardiovascular complications from nonionic contrast media was 0.2% and 0.7%, respectively. The mean serum creatinine level increased 11.5 mumol/L from baseline at 24 hours (P less than 0.0001) and 16.8 mumol/L from baseline at 48 hours (P less than 0.0001). Results in a randomly selected training sample were studied to determine predictors of a rise in serum creatinine of 44.2 mumol/L or more. The baseline serum creatinine level and age were significant predictors of renal injury, but hypertension, diabetes mellitus, congestive heart failure, vascular disease, the volume of contrast agent injected or baseline values of urinary variables did not predict nephrotoxicity. In an independent validation sample, only the baseline serum creatinine level was confirmed as a predictor of nephrotoxicity, whereas age was not. A model that predicted contrast-induced nephropathy by the serum creatinine level showed an exponential increase in the risk for nephrotoxicity if the baseline level was 106.1 mumol/L or higher.
Patients have a small but significant rise in serum creatinine after cardiac catheterization with a nonionic contrast agent. Baseline renal insufficiency is the only confirmed predictor of nonionic contrast-induced nephrotoxicity.
确定非离子型造影剂用于心脏导管插入术时心血管和肾脏毒性的发生率,并评估电解质和尿液分析结果作为造影剂诱发肾病预测指标的价值。
采用标准对照的非随机试验和为期48小时随访的队列分析研究。
以转诊为主的大学医院。
进行诊断性心脏导管插入术的便利样本患者。对1144例患者在基线时评估肾功能和临床状况;1077例(94%)在24小时时评估;663例(57%)在48小时时评估。
患者接受生理盐水水化后,使用碘帕醇(平均剂量,203±56毫升)进行冠状动脉造影和左心室造影。
非离子型造影剂引起的主要急性心血管并发症的明确发生率和可能发生率分别为0.2%和0.7%。血清肌酐平均水平在24小时时较基线升高11.5微摩尔/升(P<0.0001),在48小时时较基线升高16.8微摩尔/升(P<0.0001)。对随机选取的训练样本结果进行研究,以确定血清肌酐升高44.2微摩尔/升或更高的预测指标。基线血清肌酐水平和年龄是肾损伤的显著预测指标,但高血压、糖尿病、充血性心力衰竭、血管疾病、注入造影剂的量或尿液变量的基线值均不能预测肾毒性。在独立验证样本中,只有基线血清肌酐水平被确认为肾毒性的预测指标,而年龄则不是。根据血清肌酐水平预测造影剂诱发肾病的模型显示,如果基线水平为106.1微摩尔/升或更高,肾毒性风险呈指数增加。
使用非离子型造影剂进行心脏导管插入术后,患者血清肌酐虽有小幅但显著升高。基线肾功能不全是已确认的非离子型造影剂诱发肾毒性的唯一预测指标。